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We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respi-
mat inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose
inhaler (MDI) and ipratropium Respimat inhaler in patients with COPD.
This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-
group, active-controlled study. Patients with moderate to severe COPD were randomized to
ipratropium bromide/albuterol (20/100 mcg) Respimat inhaler, ipratropium bromide/albu-
terol MDI [36 mcg/206 mcg (Combivent Inhalation Aerosol MDI)], or ipratropium bromide
(20 mcg) Respimat inhaler. Each medication was administered four times daily. Serial spirom-
etry was performed over 6 h (0.15 min, then hourly) on 4 test days. The primary efficacy vari-
able was forced expiratory volume in 1 s (FEV1) change from test day baseline at 12 weeks.714 4045.
care.org (R. ZuWallack).
0 Elsevier Ltd. All rights reserved.
1180 R. ZuWallack et al.A total of 1209 of 1480 randomized, treated patients completed the study; the majority
were male (65%) with a mean age of 64 yrs and a mean screening pre-bronchodilator FEV1
(percent predicted) of 41%. Ipratropium bromide/albuterol Respimat inhaler had compa-
rable efficacy to ipratropium bromide/albuterol MDI for FEV1 area under the curve at 0e6 h
(AUC0e6), superior efficacy to ipratropium Respimat
 inhaler for FEV1 AUC0e4 and comparable
efficacy to ipratropium Respimat inhaler for FEV1 AUC4e6. All active treatments were well
tolerated.
This study demonstrates that ipratropium bromide/albuterol 20/100 mcg inhaler adminis-
tered four times daily for 12 weeks had equivalent bronchodilator efficacy and comparable
safety to ipratropium bromide/albuterol 36 mcg/206 mcg MDI, and significantly improved lung
function compared with the mono-component ipratropium bromide 20 mcg Respimat inhaler.
[Clinical Trial Identifier Number: NCT00400153]
ª 2010 Elsevier Ltd. All rights reserved.Introduction
The effective treatment of patients with airway disease
such as chronic obstructive pulmonary disease (COPD)
requires efficient delivery of medical aerosols to the lungs.
Inhaled bronchodilators, the cornerstone treatment for
COPD, are commonly delivered to the lungs via metered
dose inhalers (MDI) which utilize chlorofluorocarbons (CFC)
or hydrofluoroalkane (HFA) propellants to generate an
aerosolized medication. Respimat inhalation spray is
a propellant-free, multi-dose inhaler designed as an alter-
native to MDIs. It uses mechanical energy from a pre-
tensioned spring to generate a medical aerosol, rather
than CFC propellants which contribute to ozone-depletion,
with subsequent negative environmental and public health
impacts.
The Respimat inhaler generates a slow moving aero-
sol over 1.5 s facilitating coordination with inhalation and
a fine particle spray (<5.8 mm), improving efficiency of
drug delivery to the lungs.1,2 Studies have shown that
lung deposition was approximately doubled and oropha-
ryngeal deposition was significantly reduced with Respi-
mat inhaler compared to MDI.3e5 Use of the Respimat
inhaler is independent of inspiratory effort and the
device provides the patient with a dose indicator,
a locking mechanism that prevents delivery of partial
doses; and for ipratropium bromide/albuterol Respimat
inhaler (20/100 mcg), the convenience of single puff
dosing.
Clinical studies have established that a combination
therapy of ipratropium bromide, an anticholinergic bron-
chodilator, and albuterol, a b2-adrenergic bronchodilator,
results in an additive bronchodilator effect.6,7 Use of the
combination therapy also results in improved patient
outcomes (fewer Emergency Room visits, hospitalizations
and a subsequent reduction in hospital length of stay) and
compliance, compared with concomitant use of separate
ipratropium and albuterol MDIs.8
The aim of this study was to determine the efficacy
and safety of the Respimat inhaler during combination
treatment with ipratropium bromide/albuterol 20 mcg/
100 mcg versus ipratropium bromide/albuterol 36 mcg/
206 mcg MDI (Combivent MDI) and the mono-component
ipratropium 20 mcg Respimat inhaler in patients
with moderate to severe COPD during a 12-week study
period.Methods
Sample
Male and females aged 40 years with COPD (forced expi-
ratory volume in 1 s [FEV1] 65% predicted normal and
FEV1/Forced vital capacity [FVC] 70%) and a smoking
history of 10 pack-yrs were included. Patients with
a confounding disease that would put the patient at risk
because of study participation or potentially influence the
results of the study were excluded. Other exclusion criteria
included: known hypersensitivity to anticholinergic or beta-
agonist therapy; concomitant use of drugs contraindicated
with anticholinergic or beta-agonist therapy; elevated
blood eosinophil count (600/nm3); respiratory infection
within 6 weeks prior to screening; regular daytime oxygen
therapy; use of antihistamines, oral corticosteroids at
unstable doses (i.e. <6 weeks on a stable dose or exceeding
the equivalent of prednisone 10 mg daily), initiation of
inhaled steroid or change in dose< 6 weeks prior to
screening; use of beta-blockers, monoamine oxidase (MAO)
inhibitors, tricyclic antidepressants< 30 days before base-
line period or during treatment period. Long-acting and
short-acting inhaled anticholinergic agents and long-acting
beta agonists were not allowed during the conduct of the
study. All patients were provided with albuterol MDI to use
as needed.Study design
A multinational (13 countries), multi-center (179 centers),
randomized, double-blind, double-dummy, parallel design,
active controlled non-inferiority study was performed to
compare efficacy and safety of orally inhaled ipratropium
bromide/albuterol 20 mcg/100 mcg Respimat inhaler with
ipratropium bromide/albuterol 36 mcg/206 mcg MDI (Com-
bivent MDI) and ipratropium bromide 20 mcg Respimat
inhaler in patients with moderate-to-severe COPD.
Following an initial screening visit and a 2-week run-in
phase with ipratropium bromide MDI (two actuations of
17 mcg, 4 times daily) and albuterol MDI as needed, eligible
patients were randomized to receive ipratropium bromide/
albuterol (1 actuation of 20 mcg/100 mcg) Respimat
inhaler plus placebo MDI (2 actuations), ipratropium
bromide/albuterol MDI (2 actuations of 18 mcg/103 mcg)
Ipratropium bromide/albuterol Respimat inhaler in COPD 1181plus placebo Respimat inhaler (1 actuation), or ipra-
tropium bromide Respimat inhaler (1 actuation of 20 mcg)
plus placebo MDI (2 actuations) for 12 weeks (Fig. 1). All
formulations were taken four-times daily: arising, mid-day,
early evening, before retiring. The double-dummy design
ensured that all patients handled both inhalers equally
often and prevented both investigators and patients from
differentiating active drug from placebo, despite the
different inhaler devices.
Ipratropium bromide/albuterol inhalation solution
(20 mcg/100 mcg), placebo inhalation solution, and ipra-
tropium bromide inhalation solution (20 mcg) cartridges
were supplied by Boehringer Ingelheim Pharma GmbH &
Co., Ingelheim, Germany. Respimat inhalers were
provided by Boehringer Ingelheim Micro Part, Dortmund,
Germany. Ipratropium bromide/albuterol sulfate inhalation
aerosol (18/103 mcg through the mouth piece) and placebo
inhalation aerosol were supplied by Boehringer Ingelheim
Pharmaceuticals, Ridgefield, CT. The studies took place in
November 2006eApril 2008 and were conducted in accor-
dance with the Declaration of Helsinki (1996) and GCP. All
patients provided written informed consent prior to
participation in the study and the study was approved by
the institutional ethics review boards used by participating
investigators. The study was sponsored by Boehringer
Ingelheim.
Efficacy endpoints
The three co-primary endpoints in this study included FEV1
change from test-day baseline at Day 85 for: (1) ipra-
tropium bromide/albuterol Respimat inhaler vs. ipra-
tropium bromide/albuterol MDI (AUC0e6 h) to show
non-inferiority, (2) ipratropium bromide/albuterol Respi-
mat inhaler vs. ipratropium bromide Respimat inhaler
(AUC 0e4 h) to show superiority of the combination of the
anticholinergic and beta-agonist agents to the mono-
component, and (3) ipratropium bromide/albuterol Respi-
mat inhaler vs. ipratropium bromide Respimat inhaler
(AUC4e6 h) to show non-inferiority to the mono-
component. Change from test-day baseline is the post-
dose FEV1 compared to pre-dose value on the same test
day. The latter endpoint analysis was chosen to assure that
there was no difference in bronchodilator efficacy evenFigure 1 Overall scheme of the study design. During the 2 wee
a dosage of 17 mcg, two actuations q.i.d. and albuterol MDI as nee
medication q.i.d.: on arising, mid-day, early evening, and before r
*1 actuation; y2 actuations; z as needed.4e6 h after drug administration between the combination
therapy of ipratropium bromide/albuterol Respimat
compared to the monotherapy of ipratropium bromide
Respimat. Pulmonary function tests (PFT) were conducted
15 min pre-treatment, 15, 30, 60 min, and 2, 3, 4, 5, 6 h
after drug administration at the end of the 2-week baseline
period, Day 29, 57, and 85. Spirometry was performed in
accordance with American Thoracic Society criteria.9,10
Secondary endpoints included FEV1 at Day 1, 29, 57,
peak FEV1 (maximum FEV1 value within the first 2 h after
study drug administration), peak FEV1 response (the
maximum change in FEV1 from test-day baseline within the
first 2 h after study drug administration), time to peak FEV1
response, median time to onset of a therapeutic response,
median duration of therapeutic response, FVC AUC0e6,
AUC0e4, AUC4e6, and peak FVC response (maximum change
in FVC from test-day baseline within the first 2 h after study
drug administration) on Day 1, 29, 57, 85. For the purpose
of this study, a therapeutic response during the 6-h PFT day
was considered to have been achieved if a FEV1 measure-
ment of at least 1.15 times the pre-dose value was recorded
at any time during the first 2 h of observation. Termination
of therapeutic response was defined as the first fall below
1.15 times pre-dose FEV1 on two consecutive measurements
after therapeutic response.
Safety endpoints
Adverse and serious adverse events were monitored
throughout the 2 week baseline and 12 week treatment
period. Pulse rate and blood pressure were measured at
baseline and on each test day (Day 1, 29, 57, 85) before
PFT. Baseline and end-of-study (week 12) physical exami-
nation and electrocardiogram were also recorded.
Statistical analysis
The three co-primary endpoints were analyzed using anal-
ysis of covariance (ANCOVA) with fixed effects for treat-
ment and pooled investigator site and day 1 baseline as
a covariate. Using a standard deviation of 180 mL for each
of the three co-primary endpoints, the sample size of 400
patients per treatment group provided a 97% chance of
rejecting each of the three null hypotheses. Treatedk baseline run-in phase, all patients took ipratropium MDI at
ded. During the 12 week treatment period, patients took study
etiring. PFT, pulmonary function test; q.i.d., four times daily;
1182 R. ZuWallack et al.patients from the full analysis set who had valid baseline
PFT data and 4 time points PFT data during the first 3 h
after the study drug administration on at least 1 test day
were included in the AUC0e6 and AUC0e4 efficacy analysis.
As a subset of the analysis set for the AUC0e6 and AUC0e4
efficacy analysis, treated patients who had all 3 PFT data at
4, 5, 6 h after drug administration on at least 1 of the last 3
test days were included in the AUC4e6 efficacy analysis.
ANCOVA model was also used to analyze secondary
endpoints. Onset and duration of therapeutic response and
time to peak FEV1 response were summarized by simple
medians. Safety analyses were summarized descriptively.
Adverse events were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) version 10.1. In order to see
combined occurrence rates of medically related adverse
events, multiple MedDRA preferred terms were combined
into a more meaningful single clinical pre-defined collapsed
term. Randomized patients from the treated set who
received 1 dose of study medication were included in the
safety analysis.Results
Patient disposition and characteristics
A total of 2462 patients signed informed consent and were
enrolled in the study. One thousand four hundred and
eighty patients were randomized and received treatment,
and 1460 were evaluable (98.6%) (Fig. 2). BaselineFigure 2 Flow chart for patcharacteristics were comparable among randomized
treatment groups (Table 1). The mean age of the treated
patient population was 64.1 years; 65.4% of the treated
patients were male and 89.0% were white. The mean
duration of COPD was 8.4 years. All patients were current
smokers (nZ 600, 41.1%) or ex-smokers (nZ 860, 58.9%)
with a mean percent predicted FEV1 of 41.4% and mean
FEV1/FVC of 44.8% at screening. The percentages of
patients taking any pulmonary medication were balanced
across the three treatment groups. Most frequently used
classes of concomitant pulmonary medications at the time
of screening were inhaled short-acting beta agonists (62%),
inhaled corticosteroids (44%), inhaled short-acting anti-
cholinergic agents (38%), inhaled long-acting beta agonists
(31%). Less frequently used were: methylxanthines (10%),
inhaled long-acting anticholinergic agents (9%), and oxygen
(4%). Long-acting inhaled anticholinergic agents and long-
acting beta agonists were not allowed during the conduct
of the study. The withdrawal rates were similar for the
three treatment groups (12.6% ipratropium Respimat
inhaler; 11.2% ipratropium bromide/albuterol MDI; 9.9%
ipratropium bromide/albuterol Respimat inhaler).
Spirometry
Comparable bronchodilation was achieved with ipratropium
bromide/albuterol Respimat inhaler and ipratropium
bromide/albuterol MDI as shown by FEV1 change from test-
day baseline from 0e6, 0e4 and 4e6 h at 12 weeks,
respectively (Fig. 3A).ients evaluated for study.
Table 1 Demographics and characteristics of study population.
Variablea Ipratropium
bromide/albuterol
Respimat inhaler
(nZ 486)
Ipratropium
bromide/albuterol
MDI (nZ 491)
Ipratropium
Respimat
inhaler
(nZ 483)
Male [N (%)] 316 (65.0) 322 (65.6) 317 (65.5)
Age (years) 63.8 64.23 64.3
Current smoker [N (%)] 211 (43.4) 188(38.3) 201 (41.6)
Smoking history (pack-years) 51.7 52.4 55.4
COPD duration (years) 8.2 8.6 8.5
FEV1 (L) 1.154 (0.418) 1.162 (0.426) 1.117 (0.416)
FVC (L) 2.617 (0.823) 2.600 (0.802) 2.559 (0.811)
FEV1 (% predicted) 41.5 (12.3) 41.9 (12.5) 40.9 (12.7)
FEV1/FVC (%) 44.7 (10.6) 45.3 (11.1) 44.3 (10.6)
FEV1 (L reversibility at 30 min
following 400 mg albuterol)
0.217 0.216 0.217
Patients taking pulmonary
medication at screening (>25%) [N(%)]
389 (80) 393 (80) 390 (80.7)
b-adrenergics, short acting 301 (61.9) 296 (60.3) 301 (62.3)
b- adrenergics, long acting 153 (31.5) 138 (28.1) 160 (33.1)
Inhaled steroids 214 (44.0) 215 (43.8) 218 (45.1)
Anticholinergics, short acting 197 (40.5) 179 (36.5) 180 (37.3)
Patients taking concomitant
pulmonary medication (>25%) during 12 weeks
246 (50.6) 233 (47.5) 242 (50.1)
Inhaled steroids 187 (38.5) 185 (37.7) 188 (38.9)
There were no noticeable differences among the three treatment groups.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
a Mean (SD) unless otherwise stated.
Ipratropium bromide/albuterol Respimat inhaler in COPD 1183On test Day 85, the ipratropium bromide/albuterol
Respimat inhaler group was non-inferior to the ipratropium
bromide/albuterol MDI group at 0e6 h, and was superior to
the ipratropium Respimat inhaler group with a difference
of 0.047 l (P< 0.0001) at 0e4 h in favor of ipratropium
bromide/albuterol Respimat inhaler. At 4e6 h, the bron-
chodilation achieved with ipratropium bromide/albuterol
Respimat inhaler group was non-inferior to that achieved
with the mono-component ipratropium Respimat inhaler
group (Fig. 3B).
Ipratropium bromide/albuterol Respimat inhaler
significantly improved FEV1 compared with the mono-
component ipratropium Respimat inhaler at 0e4 and 0e
6 h on all test days. (Fig. 4)
The results from the secondary FEV1 and FVC endpoints
were consistent with the primary FEV1 data. Peak FEV1,
peak FEV1 response (Fig. 5), and peak FVC response were
comparable between ipratropium bromide/albuterol
Respimat inhaler and ipratropium bromide/albuterol MDI
and superior to ipratropium Respimat inhaler (<0.0001) on
all test days. The median time to onset of therapeutic
response occurred approximately 13 min after study drug
administration for both ipratropium bromide/albuterol
Respimat inhaler and ipratropium bromide/albuterol MDI.
The overall median time to a peak response was compa-
rable across the three treatment groups: 60 min after study
drug administration on all tests days for ipratropium
bromide/albuterol Respimat inhaler and MDI; 2 h after
study drug administration for ipratropium Respimat
inhaler on test Days 1 and 29 and 60 min on test Days 57 and85. Median duration of a therapeutic response was
comparable between ipratropium bromide/albuterol
Respimat inhaler (165e189 min) and MDI (172e219 min)
overall test days, which was longer compared with ipra-
tropium Respimat inhaler (70e122 min). Seventy-six
percent (nZ 358), 74% (nZ 357) and 63% (nZ 295) of
patients treated with ipratropium bromide/albuterol
Respimat inhaler and MDI and ipratropium Respimat
inhaler, respectively, had an FEV1 increase 15% above
their baseline on Day 85 and within the first 2 h after study
drug administration.
Safety
Exposure across treatment groups was similar with a mean
of 80.1 days. The total incidence of adverse events was
comparable across treatment groups (Table 2). Respiratory
events were the most frequently reported adverse events
and were predominately comprised of COPD exacerbations.
There were no differences among the treatment groups in
the frequency of potential anticholinergic class adverse
events (2.1% ipratropium Respimat inhaler, 2.0% ipra-
tropium bromide/albuterol MDI, 1.6% ipratropium bromide/
albuterol Respimat inhaler). The majority of these events
were dry mouth (0.7%) and tremor (0.3%). The highest
frequency of possible beta-agonist-related adverse events
occurred in the ipratropium Respimat inhaler group
(9.1%), whereas both ipratropium bromide/albuterol groups
were comparable (7.2% and 7.5% ipratropium bromide/
albuterol Respimat inhaler and MDI, respectively, non-
Figure 3 A. Day 85 mean FEV1 (L) response between 0e6 h
post-dose following treatment with ipratropium bromide/
albuterol Respimat inhaler, ipratropium bromide/albuterol
MDI, and ipratropium Respimat inhaler. Data are expressed as
change from baseline after 12 weeks of treatment. Missing
data were imputed by carrying either the lowest or last value
forward depending on why the data were missing. Means (SE)
were adjusted for treatment baseline and pooled centre
(fixed). A separate ANCOVA was fitted for each time point and
test day. FEV1, forced expiratory volume in 1s. Test day 85
baseline FEV1 (in liters) was 1.112. 1.106 and 1.114 for ipra-
tropium bromide/albuterol Respimat inhaler, ipratropium
bromide/albuterol MDI, and ipratropium bromide Respimat
inhaler, respectively. B. Day 85 mean treatment differences
and 95% confidence intervals for three primary efficacy
endpoints. Ipratropium bromide/albuterol Respimat inhaler
group was superior to the ipratropium Respimat inhaler group
with a difference of 0.047 l (P< 0.0001) at 0e4 h.
1184 R. ZuWallack et al.significant). The occurrences of headache, dizziness,
nausea and hypertension were the most frequent possible
beta-agonist adverse events across all treatment groups.
The percentage of patients who discontinued due to an
adverse event was lower in the ipratropium bromide/albu-
terol Respimat inhaler group: ipratropium bromide/albu-
terol Respimat inhaler (3.7%), ipratropium bromide/
albuterol MDI (6.9%), ipratropium Respimat inhaler (6.8%).
Lower respiratory system disorders were the most frequent
adverse event leading to treatment discontinuation (3.9%)
and occurred with the lowest frequency in the ipratropiumbromide/albuterol Respimat inhaler group (2.5%)
compared with ipratropium bromide/albuterol MDI (4.3%)
and ipratropium Respimat inhaler (5.0%). COPD exacerba-
tions (2.7%) accounted for the majority of lower respiratory
system disorder leading to treatment discontinuation.
A total of 64 patients (4.4%) experienced 1 serious
adverse event, with a higher frequency occurring in the
ipratropium bromide/albuterol MDI arm (6.7%) versus ipra-
tropium bromide/albuterol Respimat inhaler (3.5%) and
ipratropium Respimat inhaler (2.9%). Lower respiratory
events were the most frequent (ipratropium bromide/
albuterol Respimat inhaler: 2.7%, ipratropium bromide/
albuterol MDI: 3.7%, ipratropium Respimat inhaler: 2.3%)
with COPD exacerbations accounting for the majority of
events (ipratropium bromide/albuterol Respimat inhaler:
2.3%, ipratropium bromide/albuterol MDI: 2.6%, ipra-
tropium Respimat inhaler: 1.7%).
Three deaths occurred on treatment in the ipratropium
bromide/albuterol Respimat inhaler group: one from
pneumonia, one from a COPD exacerbation with respiratory
failure, and one with an unknown cause. There was one
homicide-related death in the MDI group, and two deaths in
the ipratropium bromide Respimat inhaler group: one
from brain cancer and one from small cell lung cancer.
None of the deaths were considered related to study
treatment. There were no clinically significant differences
in vital signs for all treatment groups.Discussion
The aim of our study was to determine the efficacy and
safety of ipratropium bromide/albuterol delivered via the
Respimat inhaler compared with this bronchodilator
combination delivered by MDI and with ipratropium alone
via the Respimat inhaler. Test drugs were administered
four times daily in patients with moderate to severe COPD
over a 12-week study period. Since we included ipratropium
in all three treatment arms, our study was not designed to
evaluate the efficacy or safety of this drug. Rather, we
were interested in evaluating its combination with albu-
terol delivered via this novel delivery device.
Previous dose-ranging studies and a Phase III trial indi-
cated that a higher dose of ipratropium bromide/albuterol
administered via the Respimat inhaler (40 mcg/200 mcg)
was also more effective than the monotherapy of ipra-
tropium bromide (40 mcg) Respimat inhaler but provided
minimal additional bronchodilator effect over the ipra-
tropium bromide/albuterol Respimat inhaler 20/100 mcg
dose chosen for our study.11 Additionally the 40/200 mcg
dose was equivalent in bronchodilator activity to that of
the MDI (36 mcg/206 mcg) formulation, a goal of the
formulation, since the Respimat inhaler is intended as an
alternative to the MDI.11
Pharmacokinetic data from our study has shown
comparable ipratropium bromide systemic exposure for all
three investigational treatments of this trial, and less
systemic exposure for albuterol with ipratropium bromide/
albuterol Respimat inhaler (20 mcg/100 mcg) than that
with ipratropium bromide/albuterol MDI (36/206 mcg).12
The 20 mcg dose of ipratropium with 100 mcg of albuterol
maintained the 1:5 ratio of ipratropium bromide to
Figure 4 Mean FEV1 (l) response between 0e6 h post-dose following treatment with ipratropium bromide/albuterol Respimat

inhaler, ipratropium bromide/albuterol MDI, and ipratropium Respimat inhaler on test Day 1, 29, 57, and 85. Data are expressed as
change from baseline. Missing data were imputed by carrying either the lowest or last value forward depending on why the data
were missing. Means (SE) were adjusted for treatment baseline and pooled centre (fixed). A separate ANCOVA was fitted for each
time point and test day. FEV1, forced expiratory volume. Standard error was comparable across treatment groups and time points
ranging from 0.007 to 0.009 l.
Figure 5 Mean peak FEV1 (l) response within the first 2 h
after administration of ipratropium bromide/albuterol Respi-
mat inhaler, ipratropium bromide/albuterol MDI, and ipra-
tropium Respimat inhaler on test Day 1, 29, 57, and 85. Data
are expressed as change from baseline after 12 weeks of
treatment. FEV1, forced expiratory volume in 1 s. Standard
error was 0.008 l across treatment groups and time points.
Ipratropium bromide/albuterol Respimat inhaler in COPD 1185albuterol in the currently marketed product ipratropium
bromide/albuterol MDI (Combivent MDI) as well as the
marketed mono-products (34 mcg ipratropium and 180 mcg
albuterol base). Ipratropium bromide Respimat inhaler
(20 mcg) has been shown to be clinically comparable to
ipratropium bromide MDI (36 mcg Atrovent CFC Inhalation
Aerosol).13
Our results indicate that after 12 weeks of treatment
equivalent bronchodilation was achieved with ipratropium
bromide/albuterol via Respimat inhaler and ipratropium
bromide/albuterol via MDI. Additionally, the bronchodilator
combination via Respimat inhaler produced greater
bronchodilation than ipratropium alone administered by
this inhaler. Albuterol and ipratropium delivered by Respi-
mat inhaler and MDI also had similar efficacy in peak FEV1
response, median time to onset of therapeutic response,
median duration of therapeutic response, and percentage
of patients who achieved a therapeutic response within two
hours of administration. The fixed combination treatment
via either Respimat inhaler or MDI reduced the median
time to onset of therapeutic response and median time to
peak response and prolonged the median duration of
therapeutic response compared to ipratropium alone given
Table 2 Number (%) of patients with adverse events (3%) in any treatment group.
System organ
class/preferred term
Ipratropium
bromide/albuterol
Respimat inhaler
(nZ 486)
Ipratropium
bromide/albuterol
MDI (nZ 491)
Ipratropium
Respimat inhaler
(nZ 483)
Total treated
(nZ 1460)
Total with any AE 222 (45.7) 254 (51.7) 215 (44.5) 691 (47.3)
Lower respiratory
disordersa
105 (21.6) 107 (21.8) 89 (18.4) 301 (20.6)
COPD exacerbationb 72 (14.8) 64 (13.0) 50 (10.4) 186 (12.7)
Bronchitisb 14 (2.9) 17 (3.5) 7 (1.4) 38 (2.6)
Upper respiratory
disordersa
64 (13.2) 76 (15.5) 62 (12.8) 202 (13.8)
Nasopharyngitis 18 (3.7) 15 (3.1) 20 (4.1) 53 (3.6)
Upper respiratory
tract infectionb
17 (3.5) 19 (3.9) 18 (3.7) 54 (3.7)
Nervous system
disordersa
21 (4.3) 28 (5.7) 33 (6.8) 82 (5.6)
Headache 13 (2.7) 10 (2.0) 16 (3.3) 39 (2.7)
There were no noticeable differences among the three treatment groups.
AE, adverse event.
a All primary system organ classes are defined by MedDRA with the exception of ‘Respiratory, thoracic and mediastinal disorders’ which
are divided into separate categories of respiratory system disorders, Lower, Upper and Other.
b Collapsed terms include multiple MedDRA preferred terms.
1186 R. ZuWallack et al.by Respimat inhaler. Likewise, a higher percentage of
patients achieved therapeutic response within the first 2 h
after administration of combination study medication via
either inhaler versus the mono-component. All secondary
spirometry endpoints (FEV1 and FVC) were consistent with
that observed in the primary FEV1 efficacy endpoints.
The overall adverse event frequencies were compa-
rable across treatment groups, with slightly higher
frequencies in the ipratropium bromide/albuterol MDI
treated patients. Lower respiratory system events were
the most frequently reported events and were comprised
mainly of COPD exacerbations. These events occurred at
comparable rates in the ipratropium bromide/albuterol
groups and a slightly lower frequency in the ipratropium
Respimat inhaler treated patients. The most commonly
reported SAE was COPD exacerbation (2.2%), which was
distributed evenly across treatment groups; this finding is
consistent with previous studies of similar patient
groups.14e17 There was also a low rate of discontinuation
due to adverse events with no notable differences in
discontinuation patterns between treatment groups, and
the majority of events causing discontinuation in the trial
were lower respiratory system disorders. Adverse events
consistent with potential anticholinergic (ipratropium)
class events were observed infrequently and occurred
similarly across all three treatment groups. Headache,
consistent with the possible beta agonist class effect of
albuterol, was the most commonly reported adverse event
in this trial and occurred with the highest frequency in the
ipratropium Respimat inhaler group (the group with no
beta agonist administration). Overall, there were no
clinically significant differences in the safety profiles
among ipratropium bromide/albuterol Respimat inhaler,
ipratropium bromide/albuterol MDI, and the ipratropium
Respimat inhaler. All three treatments were well-
tolerated.A patient assessment questionnaire showed that the
majority of patients in the trial preferred the Respimat
inhaler to MDI.18 This finding is consistent with previous
studies demonstrating ease of use, improved patient inha-
lation technique and patient preference for Respimat
inhaler over MDIs or DPIs.19e21 In addition, end of use
testing of the Respimat inhaler demonstrated reliable
near end of use performance for dosing behavior for volume
accuracy and particle size fraction.22 Pharmacokinetic
analysis showed increased efficiency with a lower dose of
ipratropium bromide/albuterol in the Respimat inhaler
compared to the MDI and improved delivery of drug to the
lungs23 consistent with previous studies evaluating drug
deposition via Respimat inhaler.1e5,24 These data demon-
strated that Respimat inhaler is a convenient and reliable
inhaler for COPD patients.
In summary, this 12 week study demonstrated that
ipratropium bromide/albuterol (20 mcg/100 mcg) delivered
by the Respimat inhaler had comparable efficacy and
safety to the same drug combination (ipratropium bromide/
albuterol) at a dose of 36 mcg/206 mcg delivered by an MDI.
Furthermore, the combination delivered by Respimat
inhaler had superior efficacy to the mono-component
ipratropium delivered by this inhaler. This study indicates
that ipratropium bromide/albuterol Respimat inhaler
(20 mcg/100 mcg) administered as one inhalation q.i.d. is
as effective and safe as the reference MDI (Combivent
MDI) for use in patients with moderate to severe COPD.Conflict of interest statement
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